Plos Med:在疟疾高发区域,对孕妇进行疟疾快速诊断,似乎没啥用

2016-09-15 Mechront 译 MedSci原创

在非洲,大多数孕期的疟原虫感染都是无症状的,却与产妇贫血和低出生体重息息相关。WHO建议:孕期使用磺胺多辛-乙胺嘧啶(IPTp-SP)进行间歇性预防治疗。但是磺胺多辛-乙胺嘧啶(SP)的有效性与寄生虫含量有关。我们进行了一项研究,评估疟疾快速诊断方式(RDTs)在间歇性筛查疟疾的有效性,以及使用双氢青蒿素-哌喹(DP;IPTp-SP的另一种治疗选择)对RDT阳性女性的疗效和安全性。 干预组女

在非洲,大多数孕期的疟原虫感染都是无症状的,却与产妇贫血和低出生体重息息相关。WHO建议:孕期使用磺胺多辛-乙胺嘧啶(IPTp-SP)进行间歇性预防治疗。但是磺胺多辛-乙胺嘧啶(SP)的有效性与寄生虫含量有关。我们进行了一项研究,评估疟疾快速诊断方式(RDTs)在间歇性筛查疟疾的有效性,以及使用双氢青蒿素-哌喹(DP;IPTp-SP的另一种治疗选择)对RDT阳性女性的疗效和安全性。

干预组女性在孕中期和孕晚期,每隔4-6周进行一次随访,共三次或四次。IPTp-SP组参与者在每次随访时接受SP预防治疗。进行间歇性筛查和使用DP(ISTp-DP) 治疗的女性在每次随访时均进行疟疾的筛查,如果RDT阳性,就进行DP治疗。主要结果为不良出生结局(首次妊娠或第二次妊娠;小于胎龄儿、低出生体重[<2,500 g]、早产[<37周]),以及分娩时母体或胎盘疟原虫感染(≥3次妊娠)。

在2011年7月21日至2013年3月18日,共招募了1873名女性,1155名为首次妊娠或第二次妊娠,718名为≥3次妊娠。

数据显示,ISTp-DP组和IPTp-SP组的不良出生结局发生率相似(29.9% vs 28.8%;相差 1.08% [95% CI −3.25% to 5.41%];所有女性 RR 1.04 [95% CI 0.90–1.20], p = 0.625;首次妊娠或第二次妊娠女性 RR 1.10 [95% CI 0.92–1.31], p = 0.282;≥3次妊娠女性 RR 0.92 [95% CI 0.71–1.20], p = 0.543)。

ISTp-DP组女性在分娩时,疟疾患病率更高(48.7% vs 40.8%; 相差 7.85%, [95% CI 3.07%–12.63%]; 所有女性: RR = 1.19 [95% CI 1.07–1.33], p = 0.007; 首次妊娠或第二次妊娠女性: RR = 1.16 [95% CI 1.04–1.31], p = 0.011; ≥3次妊娠女性: RR = 1.29 [95% CI 1.02–1.63], p = 0.037)。

ISTp-DP组孕妇的胎儿丢失率更高(2.6% vs 1.3%; RR = 2.06 [95% CI 1.01–4.21], p = 0.046);尤其是ISTp-DP组的非DP接受者(3.1%)胎儿丢失率最高。

结果表明,在疟疾高发区域和SP耐药区域,使用母目前的RDTs对孕期女性进行三到四次疟疾筛查作为产前保健重点,并不优于IPTp-SP;此外还与更高的胎儿丢失率和分娩时更高的疟疾感染率有关。

原始出处:

Mwayiwawo Madanitsa,et al.Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial.Plos Med.Published: September 13, 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=144418, encodeId=12d91444188f, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131896, encodeId=a679131896f1, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131897, encodeId=2a3213189e5e, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131898, encodeId=b21413189824, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607100, encodeId=8213160e10060, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 17 07:42:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128968, encodeId=50981289681d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128969, encodeId=21d4128969c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-10-11 1e10c84am36(暂无匿称)

    好文章,受益

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=144418, encodeId=12d91444188f, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131896, encodeId=a679131896f1, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131897, encodeId=2a3213189e5e, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131898, encodeId=b21413189824, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607100, encodeId=8213160e10060, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 17 07:42:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128968, encodeId=50981289681d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128969, encodeId=21d4128969c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-20 xyfg98

    学习了,很好的分享,赞不停!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=144418, encodeId=12d91444188f, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131896, encodeId=a679131896f1, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131897, encodeId=2a3213189e5e, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131898, encodeId=b21413189824, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607100, encodeId=8213160e10060, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 17 07:42:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128968, encodeId=50981289681d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128969, encodeId=21d4128969c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-20 xyfg98

    学习了,很好的分享,赞不停!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=144418, encodeId=12d91444188f, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131896, encodeId=a679131896f1, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131897, encodeId=2a3213189e5e, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131898, encodeId=b21413189824, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607100, encodeId=8213160e10060, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 17 07:42:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128968, encodeId=50981289681d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128969, encodeId=21d4128969c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-20 xyfg98

    学习了,很好的分享,赞不停!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=144418, encodeId=12d91444188f, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131896, encodeId=a679131896f1, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131897, encodeId=2a3213189e5e, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131898, encodeId=b21413189824, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607100, encodeId=8213160e10060, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 17 07:42:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128968, encodeId=50981289681d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128969, encodeId=21d4128969c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=144418, encodeId=12d91444188f, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131896, encodeId=a679131896f1, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131897, encodeId=2a3213189e5e, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131898, encodeId=b21413189824, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607100, encodeId=8213160e10060, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 17 07:42:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128968, encodeId=50981289681d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128969, encodeId=21d4128969c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-16 知难而进

    谢谢分享!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=144418, encodeId=12d91444188f, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 15:09:01 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131896, encodeId=a679131896f1, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131897, encodeId=2a3213189e5e, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131898, encodeId=b21413189824, content=学习了,很好的分享,赞不停!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Sep 20 23:23:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607100, encodeId=8213160e10060, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Sep 17 07:42:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128968, encodeId=50981289681d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128969, encodeId=21d4128969c3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Fri Sep 16 22:42:00 CST 2016, time=2016-09-16, status=1, ipAttribution=)]
    2016-09-16 知难而进

    继续关注

    0

相关资讯

首种合成生物抗疟药市场遇冷

2014年,法国巴黎制药巨头赛诺菲开始出售通过基因工程合成酵母制成的抗疟疾药物,此举被认为是合成生物学的一次巨大胜利。这种酵母在一个大桶中发酵,用于生产一种可转化成青蒿素的化学物质,使其用于有效的疟疾疗法——基于青蒿素的合成疗法(ACT)。很多人希望这一过程能够提供大量廉价药物,以应对这种每年在全球导致近50万人死亡的疾病。 然而,事实上赛诺菲在2015年根本未生产任何“半合成”青蒿素。该公司现

NEJM:双氢青蒿素哌喹片用于预防怀孕时的疟疾效果良好

磺胺多辛-乙胺嘧啶间歇性治疗被广泛推荐用于非洲孕妇预防疟疾。然而,随着患者对于磺胺多辛-乙胺嘧啶抗性的增加,目前需要新的干预措施。原始出处:Abel Kakuru,Prasanna Jagannathan,Mary K. Muhindo,et al.Dihydroartemisinin–Piperaquine for the Prevention of Malaria in Pregnancy,N

Malaria:或许可从鸡的身上寻找新型疟疾预防措施

瑞典农业科学大学的Rickard Ignell和同事将研究发表在the Malaria Journal。 疟疾是由疟原虫所致的虫媒传染病,最常见的传播方式是通过按蚊叮咬感染。WHO指出,去年全球大约有2.14亿疟疾患者病例,约有438000人死于该病。撒哈拉以南非洲地区的疟疾疫情更为严重,2015年该地区的疟疾患者占全球疟疾患者的89%,占全球疟疾死亡人数的91%。 目前在高风险地区采取的的主要预

科学家为研制疟疾疫苗提供新候选抗原

20日从吉林大学获悉,该校陈启军教授团队针对恶性疟原虫逃避宿主天然免疫机理的研究取得重要进展,为研制疟疾疫苗提供了新的候选抗原,相关研究近日发表在国际著名学术期刊自然通讯上。 据介绍,天然免疫反应是机体抵御病原侵害的第一道防线。中性粒细胞(也包括巨噬细胞)被激活后可以通过一种主动性死亡的方式将染色质及胞浆内的溶酶体颗粒一起释放到胞外,形成网状结构,以捕获并杀死病原微生物。这种网状结构被命名为N

NEJM:随访7年发现疟疾疫苗的有效性并不理想

目前正在评估候选疟疾疫苗RTS,S/AS01以决定是否可将其列入常规接种程序。对于接种这些疫苗的儿童随访7年,儿童年龄为5-17个月,随机分配分别接受RTS,S/AS01疫苗或狂犬病疫苗(对照组)治疗。研究终点为临床疟疾(体温≥37.5°C,恶性疟原虫感染,寄生虫数目> 2500个/每立方毫米)。使用距离儿童家庭1公里半径以内的居民疟原虫的流行程度的信息来估计每名儿童疟疾暴露的情况。与对照组

PLoS Med:患病儿童短期补充营养没有用

 无国界医生(MSF)每年在全球治疗超过三十万名营养不良的儿童。营养不良不仅是由于缺乏食物、幼儿喂养不当,而且还由于疾病。通过给患病儿童提供营养补充来打破疾病和营养不良的恶性循环是一种潜在的有效的策略来预防营养不良,但这一策略仍没有被完全的研究透彻。因此,MSF研究了五岁以下患病儿童的营养不良发病率是否可以在两周的恢复期内降低。为此,研究人员在尼日利亚和乌干达开展了两个临床试验。&nbs